Sign in

AVLN on Nasdaq

Avalyn Pharma Inc.

American pharmaceutical preparations company based in Seattle1

In its 2026 prospectus (Form S-1) the company says: “We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation.”30 Its shares trade on Nasdaq under the symbol AVLN.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerAVLN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address105 W First St., Boston, Ma 021272
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Avalyn Pharma Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Avalyn Pharma Inc.

  • Avalyn Pharma Inc. Boston, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Avalyn Pharma Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lyn Baranowski2026–now

Chief operating officer

  1. Melissa Rhodes2026–now
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorCassandra Gianna Luca named Oct 10, 202313
  • DirectorJonathan Leff named Oct 10, 202313
  • DirectorKetan Patel named Oct 10, 202313
  • DirectorNiall O'Donnell named Oct 10, 202313
  • DirectorPeter Moldt named Oct 10, 202313
  • DirectorTiba Aynechi named Oct 10, 202313

Former names

  • Genoa Pharmaceuticals, Inc.Nov 16, 2012 to May 24, 20172

Timeline

  1. Sep 16, 20268-K Executive or director change14
  2. Aug 12, 20268-K Results of operations15
  3. Jul 1, 20268-K Entered a material agreement16
  4. Jun 17, 20268-K Regulation FD disclosure17
  5. Jun 3, 20268-K Results of operations18
  6. May 1, 20268-K Bylaws or fiscal year changed19
  7. Apr 29, 2026New chief executive Lyn Baranowski becomes CEO3

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202620

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results15
  2. Jun 3, 2026Reported quarterly or annual results18

Drug trials and FDA: coming up

  1. Dec 2026Phase 2 trial readout expected Phase 2 trial of AP02 in Idiopathic Pulmonary Fibrosis (IPF): primary completion expected Dec 2026 (ClinicalTrials.gov NCT07194382).21
  2. Jun 2027Phase 2 trial readout expected Phase 2 trial of AP01 in Pulmonary Fibrosis: primary completion expected Jun 2027 (ClinicalTrials.gov NCT06329401).22

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

57 filings to the SEC since October 2021: 2 quarterly reports, 6 major events, 31 insider forms, 7 large holders, 1 private raises, 10 other. The latest 20:

  1. Sep 17, 20264 EDGAR
  2. Sep 17, 20263 EDGAR
  3. Sep 16, 20268-K EDGAR
  4. Aug 14, 2026SCHEDULE 13G EDGAR
  5. Aug 12, 202610-Q EDGAR
  6. Aug 12, 20268-K EDGAR
  7. Aug 11, 2026SCHEDULE 13G EDGAR
  8. Aug 6, 2026SCHEDULE 13G/A EDGAR
  9. Jul 1, 20268-K EDGAR
  10. Jun 17, 20268-K EDGAR
  11. Jun 3, 202610-Q EDGAR
  12. Jun 3, 20268-K EDGAR
  13. May 8, 2026SCHEDULE 13D EDGAR
  14. May 8, 2026SCHEDULE 13D EDGAR
  15. May 7, 2026SCHEDULE 13G EDGAR
  16. May 5, 20264 EDGAR
  17. May 5, 20264 EDGAR
  18. May 5, 2026SCHEDULE 13G EDGAR
  19. May 4, 20264 EDGAR
  20. May 1, 20264 EDGAR

The 57 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 1, 2026Novo Holdings A/S10% ownerBuy555,555$18.00$10.0MForm 4
May 1, 2026Carroll JillDirectorBuy277,778$18.00$5.0MForm 4
May 1, 2026George Simeon10% ownerBuy555,555$18.00$10.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$189.2M 2023–2023
Money received by yearMoney received by year, 2023–2023: $189.2M in all. Private raises (Form D) $189.2M.$0$50M$100M$150M$200M2023 · Private raises (Form D): $189.2M2023
Figures by year
YearPrivate raises (Form D)Total
2023$189.2M$189.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 22, 2023Raised $189.2 million in a private offering of equity13 Form D: 26 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 92. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC5,835,259$192.1M0.0%New
Novo Holdings A/s3,883,289$127.8M7.4%New
SR One Capital Management, LP3,308,649$108.9M10.5%New
Perceptive Advisors LLC2,675,296$88.1M1.4%New
Montanova Capital, LLC2,503,109$82.4M1.7%New
Nvp Associates, LLC2,268,404$74.7M22.8%New
Wellington Management Group Llp2,201,986$72.5M0.0%New
Catalio Capital Management, LP1,675,830$55.2M10.4%New
Eventide Asset Management, LLC1,375,486$45.3M0.6%New
Bellevue Group AG1,350,000$44.4M0.9%New
BlackRock, Inc.977,264$32.2M0.0%New
Pivotal bioVenture Partners Investment Advisor LLC966,792$31.8M10.3%New
Citadel Advisors LLC959,098$31.6M0.0%New
Andera Partners929,824$30.6M14.8%New
Jennison Associates LLC812,749$26.8M0.0%New
Braidwell LP801,395$26.4M1.0%New
Tpg Gp A, LLC773,069$25.4M0.5%New
Vanguard Capital Management LLC739,770$24.4M0.0%New
Deerfield Management Company, L.P.731,000$24.1M0.3%New
Rock Springs Capital Management LP662,918$21.8M1.1%New
Geode Capital Management, LLC434,650$14.3M0.0%New
Soleus Capital Management, L.P.419,000$13.8M0.5%New
Infinitum Asset Management, LLC411,378$13.5M1.4%New
Baker Bros. Advisors LP350,000$11.5M0.1%New
Franklin Resources Inc331,684$10.9M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Avalyn Pharma Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAvalyn Pharma Inc.1
  • CIK0001540171
  • Employer ID (EIN)45-24631911
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address105 W First St., Boston, MA 021271
  • Phone(206) 707-03401
  • Shares outstanding44,333,095 as of Aug 31, 202629
  • On EDGAR sinceNov 16, 20121
  • Filings63 in all: 3 (16), 4 (15), 8-K (6), D (4), SCHEDULE 13G (4), D/A (3), 10-Q (2), S-1/A (2)1
    All 18 form types

    SCHEDULE 13D (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), EFFECT (1), S-1 (1), S-8 (1), SCHEDULE 13G/A (1)

  • Latest filingsQuarterly report (10-Q) Aug 12, 2026
    Latest 8-K (8-K) Sep 16, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30